1. Home
  2. PEW vs CING Comparison

PEW vs CING Comparison

Compare PEW & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GrabAGun Digital Holdings Inc.

PEW

GrabAGun Digital Holdings Inc.

HOLD

Current Price

$1.95

Market Cap

72.6M

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$4.69

Market Cap

70.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEW
CING
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.6M
70.2M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
PEW
CING
Price
$1.95
$4.69
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $21.20
AVG Volume (30 Days)
★ 284.3K
92.6K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 56.47
EPS
★ N/A
N/A
Revenue
★ $96,449,000.00
N/A
Revenue This Year
$6.38
N/A
Revenue Next Year
$6.53
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3.57
N/A
52 Week Low
$1.79
$3.16
52 Week High
$5.18
$11.89

Technical Indicators

Market Signals
Indicator
PEW
CING
Relative Strength Index (RSI) 42.28 44.86
Support Level $1.79 $4.21
Resistance Level $2.24 $5.20
Average True Range (ATR) 0.10 0.25
MACD 0.02 -0.00
Stochastic Oscillator 41.89 61.82

Price Performance

Historical Comparison
PEW
CING

About PEW GrabAGun Digital Holdings Inc.

GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition and related accessories. The Company's firearm products are ordered and paid for by customers online through the Company's eCommerce site and mobile app and are delivered to them on-premises through their choice of federal firearm licensed dealers nationwide. The Company's network of localized firearm dealers perform background checks on firearms purchasers and complete sales forms as mandated by federal and state firearm regulations.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: